Codexis also reported revenue of $38.92 million, exceeding expectations by 16.01%. This robust earnings report highlights Codexis’ ability to outperform market predictions. These developments ...

Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidanceThree presentations at upcoming TIDES USA ...

Over the last 7 days, the United States market has risen by 2.2%, and over the past year, it has increased by 31%, with earnings forecasted to grow annually by 17%. In light of these conditions, ...

Q1 2026 Management view Dr. Alison Moore said the company “accomplished a lot” since the prior call and plans to present “important new data on our ECO Synthesis technology” at the TIDES Conference, ...

Codexis CDXS will release its quarterly earnings report on Wednesday, 2025-08-13. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Codexis to report an earnings per ...

Codexis (NASDAQ:CDXS) reported first-quarter 2026 revenue of $15.2 million, up from $7.5 million a year earlier, as the company highlighted continued progress commercializing its ECO Synthesis enzymat ...

As of Sept. 30, institutional investors held over 86% of the outstanding shares. These include big names like BlackRock, Vanguard, and Fidelity as well as healthcare specialist funds including Vivo ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Codexis Inc. (CDXS) on Thursday reported a loss of $8.7 million in its first quarter. On a per-share basis, the Redwood City, California-based ...

Codexis outlined ongoing commercial discussions supported by a "very, very healthy" sales funnel spanning large pharma, ...

REDWOOD CITY, Calif., March 11, 2026 (GLOBE NEWSWIRE)-- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today ...

REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, ...

Wall Street finally started paying attention to Codexis (NASDAQ: CDXS) in 2017. But as investors are now being reminded, extra attention can bring extra scrutiny. While long-term investors have ...